Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Lawmakers weigh protections, oversight as they consider experimental-treatment center bill
Summary
Proponents argued SB 5 35 would provide regulatory clarity for clinics offering phase‑1 experimental treatments and boost innovation; opponents warned the bill exempts Montana licensure for some physicians, reduces oversight and raises ethical and consent concerns.
Senate Bill 5 35 prompted a multi-hour debate in the House Health and Human Services Committee as witnesses described competing priorities: greater access to innovative therapies versus protections for patients and state oversight. Senator Ken Bogner, sponsor, said the bill streamlines licensing, clarifies definitions and allows Montana to "provide a business friendly environment that supports both safety and consumer protection."
Proponents from the biotech and longevity communities described potential health and economic benefits. Dylan Livingston, founder of the Alliance for Longevity Initiatives, said the bill would allow earlier access to treatments that target age-related biology and could position Montana as a hub for innovation. He described…
Already have an account? Log in
Subscribe to keep reading
Unlock the rest of this article — and every article on Citizen Portal.
- Unlimited articles
- AI-powered breakdowns of topics, speakers, decisions, and budgets
- Instant alerts when your location has a new meeting
- Follow topics and more locations
- 1,000 AI Insights / month, plus AI Chat
